Investigational drug · Phase 2
WIN378
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for COPD (Chronic Obstructive Pulmonary Disease), Asthma.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 23, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
2
Any phase or sponsor naming "WIN378"
First trial start
2025
Jul 24, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "WIN378", any sponsor or status.
Conditions studied
As listed on its trial records.
- COPD (Chronic Obstructive Pulmonary Disease)
- Asthma
Approved drugs for the same conditions: Asthma · COPD · Respiratory
Largest trials
Live from ClinicalTrials.gov: studies naming "WIN378" as an intervention, largest first.
- Study to Evaluate the Safety, Pharmacology and Efficacy of WIN378 in Adults With Moderate or Severe AsthmaPivotal-lookingRecruiting
Windward BioIndustry
NCT07120503 · 600 participants (planned) · Start Jul 24, 2025 · Primary completion Oct 1, 2028
Drug: WIN378; Placebo · For: Asthma
Sites: Los Angeles, California; San Jose, California; Melbourne, Florida · 73 sites in all
- A Study of WIN378 in Participants With Moderate to Severe COPD (Sirius)Pivotal-lookingRecruiting
Windward BioIndustry
NCT07646587 · 105 participants (planned) · Start Jun 2, 2026 · Primary completion Dec 17, 2027
Drug: WIN378; Placebo · For: COPD (Chronic Obstructive Pulmonary Disease)
Sites: Los Angeles, California; Jacksonville, Florida; Miami Lakes, Florida · 32 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Safety, Tolerability, and Pharmacokinetics of HBM9378 (SKB378/WIN378), a Fully Human IgG1 Monoclonal Antibody Against TSLP After Single Ascending Doses in Chinese Healthy Subjects.
Yang X, Xu M, Cao N, et al. · Drug Des Devel Ther 2026
Also in development for COPD (Chronic Obstructive Pulmonary Disease)
- Hemay005Mufemilast, Phosphodiesterase 4 inhibitorsPhase 34 trials
Ganzhou Hemay Pharmaceutical Co., Ltd · Moderate to Severe Ulcerative Colitis, Ulcerative Colitis (UC), COPD (Chronic Obstructive Pulmonary Disease)
- HSK39004 DryPhase 34 trials
Haisco Pharmaceutical Group Co., Ltd. · Chronic Obstructive Lung Disease (COLD), COPD (Chronic Obstructive Pulmonary Disease), Chronic Obstructive Pulmonary Disease (COPD)
- BGF MDI 320BGFPhase 33 trials
AstraZeneca · Asthma, COPD (Chronic Obstructive Pulmonary Disease)
- HSK39004 Dry SimulantPhase 32 trials
Haisco Pharmaceutical Group Co., Ltd. · COPD (Chronic Obstructive Pulmonary Disease), Chronic Obstructive Pulmonary Disease (COPD)
- REGEND001Phase 32 trials
Regend Therapeutics · COPD (Chronic Obstructive Pulmonary Disease), Idiopathic Pulmonary Fibrosis
- JKN2304Phase 21 trial
Joincare Pharmaceutical Group Industry Co., Ltd · COPD (Chronic Obstructive Pulmonary Disease), COPD
- JKN24011Phase 21 trial
Joincare Pharmaceutical Group Industry Co., Ltd · COPD (Chronic Obstructive Pulmonary Disease)
- JKN2403Phase 21 trial
Joincare Pharmaceutical Group Industry Co., Ltd · COPD (Chronic Obstructive Pulmonary Disease)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.